SAN FRANCISCO — Cooley and Latham & Watkins helped close what many media outlets are calling the largest biotech IPO ever. Bermuda-based Axovant Sciences Ltd., which is working on developing a treatment for Alzheimer's, closed its initial public offering Tuesday, raising $362.3 million. The company sold 24.15 million shares of its common stock at $15 per share, including an over-allotment of 3.15 million shares sold to the underwriters.

Cooley represented Axovant in the deal with a team that included Palo Alto-based partners Frank Rahmani, John McKenna, Marya Postner and Renee Deming and associate Jennifer Raab.

A Cooley spokeswoman said attorneys could not comment because of a quiet period for their client.